Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

CAB PrEP Introduction Situation Analysis – South Africa – 2024

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.

Dynamic Choice HIV Prevention with Cabotegravir Long-acting Injectable in Rural Uganda and Kenya: A randomised trial extension

This article from The Lancet HIV discusses the results of the SEARCH dynamic choice study conducted in Kenya and Uganda, comparing outcomes between one group offered a choice between oral PrEP, post-exposure prophylaxis, and cabotegravir for PrEP, and a second group receiving the standard of care.

Access Workbook for Cabotegravir for PrEP, Dapivirine Vaginal Ring, and Lenacapavir for PrEP

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP, the dapivirine vaginal ring (DVR), and lenacapavir (LEN) for PrEP for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit…

Expanding Access to Lenacapavir

This United Advocates Network Call, titled Breaking New Ground: Expanding Access to Lenacapavir— Lessons from Dolutegravir and the Future of HIV Prevention, brought together global health experts, community advocates, and civil society organizations to discuss the challenges and opportunities in ensuring equitable access to Lenacapavir.

PrEP Method Switching: Will it Yield Greater Coverage of HIV Protection? Applying Lessons Learned from Family Planning to Guide Future Research in the Context of PrEP Choice

This review from Current HIV/AIDS Reports draws parallels between HIV prevention and family planning by summarizing how method choice and product switching affected contraceptive coverage globally, synthesizes what is known about PrEP product switching, and outlines evidence gaps to help guide future research on PrEP switching in the context of choice.

The Long Wait for Long-acting HIV Prevention and Treatment Formulations

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.

2024 Q2 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…

Client Experiences with “Dynamic Choice Prevention,” a Model for Flexible Patient-centred HIV Prevention Delivery in Rural Eastern Africa

This article from Journal of the International AIDS Society discusses client experiences of a dynamic choice model for HIV prevention piloted in Kenya and Uganda under the SEARCH study, where clients were supported to select HIV prevention method, testing mode, and service delivery channel from a range of options.

Coordinating Implementation Science for CAB for PrEP: HIV Testing

This document summarises key takeaways from a June 2024 BioPIC Think Tank to review and discuss emerging issues around cabotegravir (CAB) for PrEP implementation and HIV testing algorithms.